BHC vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health scores paint a concerning picture, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no Altman Z-Score available to confirm solvency, raising red flags. Despite a low P/E of 6.79 and forward P/E of 1.41 suggesting potential undervaluation, the negative Price/Book ratio (-3.88) implies serious equity deficiencies or accumulated losses. Strong operating and gross margins contrast sharply with a sky-high Debt/Equity ratio of 59.11, indicating extreme leverage risk. Insider selling, weak technical trend (0/100), and a 5-year price decline of 78.1% further underscore investor skepticism and structural challenges.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BHC vs JNJ: Head-to-Head Comparison
This page compares Bausch Health Companies Inc. (BHC) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.